{"id":54436,"date":"2026-04-28T08:00:00","date_gmt":"2026-04-28T01:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=54436"},"modified":"2026-04-28T08:00:00","modified_gmt":"2026-04-28T01:00:00","slug":"cordis-launches-selution-slr-pta-drug-eluting-balloon-deb-in-japan","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=54436","title":{"rendered":"Cordis Launches SELUTION SLR\u2122 PTA Drug-Eluting Balloon (DEB) in Japan"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

TOKYO<\/span>, April 28, 2026<\/span> \/PRNewswire\/ — Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the\u00a0SELUTION SLR\u2122 PTA Drug-Eluting Balloon (DEB)1 <\/sup>for use in Japan.<\/p>\n

SELUTION SLR\u2122\u00a0DEB\u00a0is designed to\u00a0deliver sirolimus in a controlled, sustained manner to reduce\u00a0restenosis and restore vessel function.\u00a0<\/p>\n

The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes in a complex patient population, including 81.5% primary patency and 93.8% of patients remaining free from reintervention\u00a0through three years.2 <\/sup>As the first sirolimus-eluting balloon approved in Japan for the treatment of peripheral artery disease, SELUTION SLR\u2122 DEB provides an additional treatment option for physicians managing patients in real-world clinical practice.\u00a0<\/p>\n

Dr. Yoshimitsu Soga,\u00a0Co-Principal Investigator of the SELUTION SFA Japan clinical trial and Director of Cardiology, Kokura Memorial Hospital\u00a0said,\u00a0“I am pleased to see SELUTION SLR\u2122 DEB now available for use in clinical practice in Japan. The three-year results from the SELUTION SFA Japan clinical trial demonstrate sustained efficacy and safety, supporting its role as an important treatment option for patients.”\u00a0<\/p>\n

Dr. Osamu Iida,\u00a0Co-Principal\u00a0Investigator of the SELUTION SFA Japan clinical trial and Director of the Department of Cardiology at Osaka International Medical & Science Center, Osaka Keisatsu Hospital\u00a0said, “SELUTION SLR\u2122 DEB is a valuable addition to the treatment options for peripheral vascular disease. In my early clinical experience, I’ve observed strong post-procedural blood flow without evidence of downstream effects below the knee. I look forward to seeing its broader adoption in real-world clinical practice.”<\/p>\n

“At Cordis, we recognize the impact peripheral artery disease can have on patients and their daily lives,” said George Adams, MD, Chief Medical Officer, Cordis. “The\u00a0launch\u00a0of SELUTION SLR\u2122 DEB in Japan reflects our focus on expanding innovative treatment options that physicians may consider based on individual patient needs. We look forward to continuing to work with the medical community in Japan to support patient care.”\u00a0<\/p>\n

About Cordis\u00a0
From the first guidewire to the first drug-eluting stent, Cordis has been at the heart of cardiovascular innovation for\u00a0nearly 70\u00a0years. Today, Cordis drives transformation through internal development, Cordis-X partnerships, and strategic acquisitions\u2014powered by a global footprint and deep operational expertise. With a focus on better clinical outcomes, customer-centered service, and impactful education,\u00a0Cordis will go beyond to relentlessly pursue its mission to transform cardiovascular care.\u00a0<\/p>\n

    \n
  1. Brand name: SELUTION SLR PTA drug-eluting balloon catheter\u00a0Medical device approval number: 30700BZI00031000<\/li>\n
  2. Soga, Y. et al. 3-Year Results Following Femoropopliteal Lesion Treatment With a Novel Sirolimus-Eluting Balloon.\u00a0JACC: Cardio Interv<\/i> 2025. 18(21):2629-2637.\u00a0<\/li>\n<\/ol>\n

    Media Contact:<\/b><\/p>\n

    Kelly May
    Director, Corporate Communications
    Cordis
    kelly.may@cordis.com<\/a>
    www.cordis.com<\/a><\/p>\n

    \"Cordis<\/a>
    Cordis Launches SELUTION SLR\u2122 PTA Drug-Eluting Balloon (DEB) in Japan<\/span> <\/div>\n

    Logo – https:\/\/mma.prnasia.com\/media2\/1676076\/5936462\/Cordis_2025_Logo.jpg?p=medium600<\/a>
    Photo –     https:\/\/mma.prnasia.com\/media2\/2965333\/Cordis__Launches_SELUTION_SLR_PTA_Drug_Eluting_Balloon_DEB_in_Japan.jpg?p=medium600<\/a><\/p>","protected":false},"excerpt":{"rendered":"

    <\/p>\n\n\n\n
    \"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    TOKYO<\/span>, April 28, 2026<\/span> \/PRNewswire\/ — Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the\u00a0SELUTION SLR\u2122 PTA Drug-Eluting Balloon (DEB)1 <\/sup>for use in Japan.<\/p>\n

    SELUTION SLR\u2122\u00a0DEB\u00a0is designed to\u00a0deliver sirolimus in a controlled, sustained manner to reduce\u00a0restenosis and restore vessel function.\u00a0<\/p>\n

    The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes in a complex patient population, including 81.5% primary patency and 93.8% of patients remaining free from reintervention\u00a0through three years.2 <\/sup>As the first sirolimus-eluting balloon approved in Japan for the treatment of peripheral artery disease, SELUTION SLR\u2122 DEB provides an additional treatment option for physicians managing patients in real-world clinical practice.\u00a0<\/p>\n

    Dr. Yoshimitsu Soga,\u00a0Co-Principal Investigator of the SELUTION SFA Japan clinical trial and Director of Cardiology, Kokura Memorial Hospital\u00a0said,\u00a0“I am pleased to see SELUTION SLR\u2122 DEB now available for use in clinical practice in Japan. The three-year results from the SELUTION SFA Japan clinical trial demonstrate sustained efficacy and safety, supporting its role as an important treatment option for patients.”\u00a0<\/p>\n

    Dr. Osamu Iida,\u00a0Co-Principal\u00a0Investigator of the SELUTION SFA Japan clinical trial and Director of the Department of Cardiology at Osaka International Medical & Science Center, Osaka Keisatsu Hospital\u00a0said, “SELUTION SLR\u2122 DEB is a valuable addition to the treatment options for peripheral vascular disease. In my early clinical experience, I’ve observed strong post-procedural blood flow without evidence of downstream effects below the knee. I look forward to seeing its broader adoption in real-world clinical practice.”<\/p>\n

    “At Cordis, we recognize the impact peripheral artery disease can have on patients and their daily lives,” said George Adams, MD, Chief Medical Officer, Cordis. “The\u00a0launch\u00a0of SELUTION SLR\u2122 DEB in Japan reflects our focus on expanding innovative treatment options that physicians may consider based on individual patient needs. We look forward to continuing to work with the medical community in Japan to support patient care.”\u00a0<\/p>\n

    About Cordis\u00a0
    From the first guidewire to the first drug-eluting stent, Cordis has been at the heart of cardiovascular innovation for\u00a0nearly 70\u00a0years. Today, Cordis drives transformation through internal development, Cordis-X partnerships, and strategic acquisitions\u2014powered by a global footprint and deep operational expertise. With a focus on better clinical outcomes, customer-centered service, and impactful education,\u00a0Cordis will go beyond to relentlessly pursue its mission to transform cardiovascular care.\u00a0<\/p>\n

      \n
    1. Brand name: SELUTION SLR PTA drug-eluting balloon catheter\u00a0Medical device approval number: 30700BZI00031000<\/li>\n
    2. Soga, Y. et al. 3-Year Results Following Femoropopliteal Lesion Treatment With a Novel Sirolimus-Eluting Balloon.\u00a0JACC: Cardio Interv<\/i> 2025. 18(21):2629-2637.\u00a0<\/li>\n<\/ol>\n

      Media Contact:<\/b><\/p>\n

      Kelly May
      Director, Corporate Communications
      Cordis
      kelly.may@cordis.com<\/a>
      www.cordis.com<\/a><\/p>\n

      \"Cordis<\/a>
      Cordis Launches SELUTION SLR\u2122 PTA Drug-Eluting Balloon (DEB) in Japan<\/span> <\/div>\n

      Logo – https:\/\/mma.prnasia.com\/media2\/1676076\/5936462\/Cordis_2025_Logo.jpg?p=medium600<\/a>
      Photo –       https:\/\/mma.prnasia.com\/media2\/2965333\/Cordis__Launches_SELUTION_SLR_PTA_Drug_Eluting_Balloon_DEB_in_Japan.jpg?p=medium600<\/a><\/p>\n

      <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-54436","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/54436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54436"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/54436\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}